RADIATION RESPONSE OF HUMAN LUNG-CANCER CELLS WITH INHERENT AND ACQUIRED-RESISTANCE TO CISPLATIN

被引:29
作者
TWENTYMAN, PR
WRIGHT, KA
RHODES, T
机构
[1] MRC Clinical Oncology and Radiotherapeutics Unit, Cambridge, CB2 2QH England, Hills Road
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1991年 / 20卷 / 02期
关键词
RADIOSENSITIVITY; LUNG CANCER; CISPLATIN; DRUG RESISTANCE; GLUTATHIONE;
D O I
10.1016/0360-3016(91)90093-J
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have derived sublines of three human lung cancer cell lines with acquired resistance to cisplatin. The cisplatin resistant sublines of NCI-H69 (small cell), COR-L23 (large cell), and MOR (adenocarcinoma) show 5.3 fold, 3.1 fold, and 3.8 fold resistance, respectively, determined in a 6-day MTT assay. Although the parent lines show a wide range of glutathione content per cell, the sublines each show similar values to their corresponding parent line. Radiation response curves have been obtained using a soft agar clonogenic assay. Values obtained for the parent lines (95% CL in parentheses) were: NCI-H69: Do = 0.99 Gy (0.87-1.16), n = 2.9 (1.6-5.2), GSH = 14 ng/10(4) cells; COR-L23: Do = 1.23 Gy (1.05-1.49), n = 1.3 (0.7-2.2), GSH = 47 ng/10(4) cells; MOR: Do = 1.66 Gy (1.48,1.88), n = 3.0 (1.9-4.8), GSH = 86 ng/10(4) cells. The cisplatin resistant variants of NCI-H69 and COR-L23 showed 31% and 63% increases, respectively, in Do compared to their parent lines, whereas no change in radiation response was seen MOR. In this panel of lines, therefore, although there is a correlation between glutathione content and radiosensitivity of the parent cell lines, acquired resistance to cisplatin is not accompanied by increased glutathione content. However, two of the three cisplatin resistant lines do show a significantly reduced radiosensitivity.
引用
收藏
页码:217 / 220
页数:4
相关论文
共 17 条
[2]   NON-PROTEIN THIOLS AND THE RADIATION RESPONSE OF A549 HUMAN-LUNG CARCINOMA-CELLS [J].
BIAGLOW, JE ;
CLARK, EP ;
EPP, ER ;
MORSEGUADIO, M ;
VARNES, ME ;
MITCHELL, JB .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1983, 44 (05) :489-495
[3]  
BULLER AL, 1987, MOL PHARMACOL, V31, P575
[4]   INVITRO COLONY ASSAY FOR HUMAN TUMORS GROWN IN IMMUNE-SUPPRESSED MICE AND TREATED INVIVO WITH CYTOTOXIC AGENTS [J].
COURTENAY, VD ;
MILLS, J .
BRITISH JOURNAL OF CANCER, 1978, 37 (02) :261-268
[5]  
ENDRESEN L, 1984, ACTA PHARMACOL TOX, V55, P183
[6]  
HABIG WH, 1974, J BIOL CHEM, V249, P7130
[7]  
LOUIE KG, 1985, CANCER RES, V45, P2110
[8]  
MATSUDA H, 1988, CANCER RES, V48, P5713
[9]  
MORSTYN G, 1984, JNCI-J NATL CANCER I, V73, P801
[10]  
MOSCOW JA, 1989, MOL PHARMACOL, V36, P22